| Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report M Brunet, T Van Gelder, A Åsberg, V Haufroid, DA Hesselink, L Langman, ... Therapeutic drug monitoring 41 (3), 261-307, 2019 | 496 | 2019 |
| Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de … R Guilhaumou, S Benaboud, Y Bennis, C Dahyot-Fizelier, E Dailly, ... Critical Care 23, 1-20, 2019 | 365 | 2019 |
| Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry P Gobin, F Lemaître, S Marchand, W Couet, JC Olivier Antimicrobial agents and chemotherapy 54 (5), 1941-1948, 2010 | 167 | 2010 |
| Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood F Lemaitre, N Hasni, P Leprince, E Corvol, G Belhabib, P Fillâtre, CE Luyt, ... Critical Care 19, 1-6, 2015 | 121 | 2015 |
| Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology S Bergan, M Brunet, DA Hesselink, KL Johnson-Davis, PK Kunicki, ... Therapeutic drug monitoring 43 (2), 150-200, 2021 | 107 | 2021 |
| Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug–drug interactions L Elens, LJ Langman, DA Hesselink, S Bergan, DJAR Moes, M Molinaro, ... Therapeutic drug monitoring 42 (3), 360-368, 2020 | 76 | 2020 |
| High intrapatient variability of tacrolimus exposure in the early period after liver transplantation is associated with poorer outcomes M Rayar, C Tron, C Jézéquel, JM Beaurepaire, A Petitcollin, ... Transplantation 102 (3), e108-e114, 2018 | 69 | 2018 |
| Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients F Lemaitre, M Antignac, C Fernandez Clinical biochemistry 46 (15), 1538-1541, 2013 | 66 | 2013 |
| Removal of colistin during intermittent haemodialysis in two critically ill patients S Marchand, JP Frat, F Petitpas, F Lemaître, P Gobin, R Robert, O Mimoz, ... Journal of antimicrobial chemotherapy 65 (8), 1836-1837, 2010 | 64 | 2010 |
| Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells F Lemaitre, B Blanchet, M Latournerie, M Antignac, P Houssel-Debry, ... Clinical Biochemistry 48 (6), 406-411, 2015 | 58 | 2015 |
| Pharmacogenetics of membrane transporters of tacrolimus in solid organ transplantation C Tron, F Lemaitre, C Verstuyft, A Petitcollin, MC Verdier, E Bellissant Clinical Pharmacokinetics 58, 593-613, 2019 | 47 | 2019 |
| Potential drug–drug interactions associated with drugs currently proposed for COVID‐19 treatment in patients receiving other treatments F Lemaitre, C Solas, M Grégoire, L Lagarce, L Elens, E Polard, ... Fundamental & Clinical Pharmacology 34 (5), 530-547, 2020 | 44 | 2020 |
| Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with … F Lemaitre, CE Luyt, F Roullet-Renoleau, A Nieszkowska, N Zahr, ... Therapeutic drug monitoring 34 (2), 171-175, 2012 | 44 | 2012 |
| Pharmacokinetic parameters of infliximab influence the rate of relapse after de‐escalation in adults with inflammatory bowel diseases A Petitcollin, C Brochard, L Siproudhis, C Tron, MC Verdier, F Lemaitre, ... Clinical Pharmacology & Therapeutics 106 (3), 605-615, 2019 | 42 | 2019 |
| How can we best monitor 5-FU administration to maximize benefit to risk ratio? F Goirand, F Lemaitre, M Launay, C Tron, E Chatelut, JC Boyer, M Bardou, ... Expert opinion on drug metabolism & toxicology 14 (12), 1303-1313, 2018 | 42 | 2018 |
| Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT) F Lemaitre, M Grégoire, C Monchaud, S Bouchet, B Saint-Salvi, E Polard, ... Therapies 77 (5), 509-521, 2022 | 41 | 2022 |
| Population Pharmacokinetics of Everolimus in Cardiac Recipients: Comedications: ABCB1:, and: CYP3A5: Polymorphisms F Lemaitre, E Bezian, L Goldwirt, C Fernandez, R Farinotti, S Varnous, ... Therapeutic drug monitoring 34 (6), 686-694, 2012 | 41 | 2012 |
| Outpatient parenteral antimicrobial therapy for infective endocarditis: a cost-effective strategy A Lacroix, M Revest, S Patrat-Delon, F Lemaître, E Donal, A Lorléac’h, ... Médecine et maladies infectieuses 44 (7), 327-330, 2014 | 40 | 2014 |
| A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics L Goldwirt, F Lemaitre, N Zahr, R Farinotti, C Fernandez Journal of pharmaceutical and biomedical analysis 66, 325-333, 2012 | 36 | 2012 |
| Ex vivo model to decipher the impact of extracorporeal membrane oxygenation on beta-lactam degradation kinetics C Leven, P Fillâtre, A Petitcollin, MC Verdier, J Laurent, N Nesseler, ... Therapeutic drug monitoring 39 (2), 180-184, 2017 | 35 | 2017 |
